A case report of euglycemic ketoacidosis due to dapagliflozin treatment

Year 2021, Volume: 3 Issue: Supplement 1, 85 - 86, 07.03.2021

Murat Çalapkulu , Muhammed Erkam Sencar , İlknur Öztürk Ünsal , Hayri Bostan , Erman Çakal

https://doi.org/10.46310/tjim.877156

Abstract

Diabetic ketoacidosis (DKA) is a leading cause of mortality and morbidity in type 2 diabetic patients. Sodium-glucose co-transporter (SGLT-2) inhibitors are a new antidiabetic treatment class that increases the renal excretion of glucose. The Food and Drug Administration issued a warning in May 2015 notifying that patients using this class of anti-diabetic drugs may develop DKA. Risk factors for DKA development among patients who take SGLT-2 inhibitors include carbohydrate intake/starvation or acute illness. In the current report, we aimed to present a case of euglycemic DKA using dapagliflozin treatment.

Keywords

Dapagliflozin, sodium-glucose co-transporter 2 inhibitors, euglycemic ketoacidosis

References

• 1. Chao EC, Henry RR. SGLT2 inhibition--a novel strategy for diabetes treatment. Nat Rev Drug Discov 2010;9(7):551–9.
• 2. Dhatariya KK, Umpierrez GE. Guidelines for management of diabetic ketoacidosis: time to revise? Lancet Diabetes Endocrinol 2017;5(5):321–3.
• 3. Yu X, Zhang S, Zhang L. Newer Perspectives of Mechanisms for Euglycemic Diabetic Ketoacidosis. Int J Endocrinol 2018;2018:7074868.
• 4. Fralick M, Schneeweiss S, Patorno E. Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. N Engl J Med 2017;376(23):2300–2.
• 5. Food and Drug Administration, FDA drug safety communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the bloodNovember 2019 http://www.fda.gov/Drugs/Drug.Safety/ucm446845.htm.
• 6. Taylor SI, Blau JE, Rother KI. SGLT2 Inhibitors May Predispose to Ketoacidosis. J Clin Endocrinol Metab 2015;100(8):2849–52.
• 7. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care 2021;44(Suppl 1):S111–24.
• 8. Burke KR, Schumacher CA, Harpe SE. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature. Pharmacotherapy 2017;37(2):187–94.